Amyris and Givaudan wrap up deal for licensing of hero ingredients

By Julia Wray | Published: 11-Apr-2023

The transaction, which will see Amyris continue to manufacture ingredients for Givaudan to use in cosmetics, was announced in February

Fragrance and beauty industry supplier Givaudan and Amyris have closed a February-announced deal which sees Givaudan acquire a portfolio of cosmetic ingredients from the synthetic biology firm. 

The ingredients in question are Neossance Squalane (an emollient); Neossance Hemisqualane (a plant-based silicone alternative); and CleanScreen (a sustainable sun protection solution).

Amyris will continue to manufacture ingredients for Givaudan to use in cosmetics and provide the company with access to its innovation capabilities.

The deal builds on a successful history between the companies that includes the development and commercialisation of the world's leading supply of bisabolol from Amyris’ fermentation platform.

Maurizio Volpi, President, Givaudan Fragrance & Beauty called the transaction an “important step” that would “reinforce our leadership in biotech”. 

John Melo, Amyris’ President and CEO, added: “Our unique biomanufactured molecules enable significant expansion to the Givaudan Active Beauty business leadership in the supply of clean, sustainable ingredients.”

Terms of the deal have not been disclosed, but Amyris’ cosmetics business would have represented approximately US$30m of incremental sales to Givaudan’s results in 2022 on a proforma basis.

You may also like